Show Summary Details
Page of

Acute lymphoblastic leukaemia 

Acute lymphoblastic leukaemia
Chapter:
Acute lymphoblastic leukaemia
DOI:
10.1093/med/9780199299676.003.26
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 22 October 2019

Incidence 396

Aetiology and prenatal origin 396

Presenting symptoms 397

Differential diagnosis 397

Investigations 398

Primary management at presentation (including clinical emergencies) 399

Treatment 400

Treatment-related complications 402

Management of relapse 403

Acute lymphoblastic leukaemia (ALL) in children is a paradigm for the development of paediatric haematology and oncology over the last 40 years. As it has evolved from being an incurable disease in the 1960s to an overall event-free survival at 5 years now approaching 80%, it has become one of the success stories of modern multi-agent chemotherapy. The history of treatment for childhood ALL highlights the importance of randomized clinical trials, since these formed the basis for the continuous improvement of ALL chemotherapy. In addition, substantial insight into the biology of childhood ALL has been gained that in the future will hopefully translate into improved and more specific treatments with fewer side effects. However, despite the excellent cure rates, ALL treatment still puts a significant burden onto affected children and their families....

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.